Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused on blood transfusion safety through its INTERCEPT Blood System and related technologies. This news page aggregates company announcements, financial updates, clinical milestones, and partnership news that Cerus releases through channels such as Business Wire and SEC-furnished press releases.
Readers can find coverage of quarterly and annual financial results, where Cerus reports product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, along with government contract revenue tied to research and development programs. These releases often include updated product revenue guidance ranges and commentary on commercial performance in various geographies.
The news flow also highlights clinical and regulatory developments, including progress of the INTERCEPT red blood cell system in late-stage clinical development, Phase 3 trials such as RedeS, and regulatory review activities in Europe and the United States. Updates on the INT200 LED-based illumination device and development of lyophilized IFC (LyoIFC), supported by U.S. Department of Defense funding, are also featured.
In addition, Cerus issues news about strategic collaborations and industry engagement, such as group purchasing agreements with organizations like Blood Centers of America and participation in professional meetings, workshops, and conferences in transfusion medicine. These items describe efforts to expand access to pathogen-protected blood components and to share data on INTERCEPT technologies.
Investors, clinicians, and other stakeholders can use this page to follow Cerus’ latest disclosures on product adoption, revenue trends, government-supported projects, and scientific presentations related to blood safety and pathogen reduction.
Cerus (Nasdaq: CERS) named Vivek Jayaraman president and chief executive officer, effective July 1, 2026, with William “Obi” Greenman moving to executive chairman.
Mr. Jayaraman, Cerus COO since 2020, grew product revenue from under $40M to over $200M in 2025; Cerus has product sales in 40+ countries and four FDA approvals in the past decade.
Cerus (Nasdaq: CERS) reported 2025 total revenue of $233.8 million (+16% YoY) and product revenue of $206.1 million (+14% YoY).
Key items: IFC revenue rose ~80% to $16.7 million, GAAP net loss narrowed to $15.6 million, non-GAAP adjusted EBITDA was $9.5 million, cash and short-term investments were $82.9 million, and 2026 product revenue guidance is $224–228 million.
Cerus Corporation (Nasdaq: CERS) said company management will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 10:30 a.m. ET. A live webcast will be available on the company Investor Relations site, with a replay accessible for 90 days.
Cerus Corporation (Nasdaq: CERS) will release fourth quarter and full-year 2025 financial results on March 2, 2026 after market close.
The company will host a conference call and webcast at 4:30 P.M. ET to discuss results, outlook, and provide presentation slides; a replay will be available through March 23, 2026.
Cerus (Nasdaq: CERS) announced the start of the INITIATE study, a prospective, multicenter, non-interventional Post-Authorization Safety Study (PASS) led by the German Red Cross Blood Donation Service Baden-Württemberg–Hessen and its North-East subsidiary.
The study is the first in Germany to evaluate routine clinical use and the safety profile of platelet concentrates treated with Cerus’ INTERCEPT Blood System, and aims to assess operational integration, routine suitability, and feasibility of broader system-wide introduction of pathogen-inactivated platelets in German hospitals.
Cerus (Nasdaq: CERS) reported preliminary unaudited product revenue of $57.8M for Q4 2025 and $206.1M for full-year 2025, each up 14% versus 2024. INTERCEPT Fibrinogen Complex (IFC) contributed $4.2M in Q4 and $16.7M for the year, increases of ~40% and ~80% year-over-year, respectively. The company expects full-year 2026 product revenue of $224M–$228M (growth of 9%–11%) and forecasts 2026 IFC revenue of $20M–$22M (≈20%–30% growth). Key 2026 milestones include an FDA PMA submission for INT200 in mid-2026 and Phase 3 RedeS RBC trial results in H2 2026. Complete audited results and a business review will be presented on a hosted call in early March 2026.
Cerus Corporation (Nasdaq: CERS) announced a group purchasing agreement with Blood Centers of America (BCA) on December 10, 2025 covering Cerus’ entire INTERCEPT product line.
The agreement covers pathogen reduction for platelets, plasma and INTERCEPT Fibrinogen Complex (IFC), and will use a resource-sharing model to move ongoing IFC production across BCA member blood centers. BCA represents 60+ independent community blood centers that produce about half of U.S. platelet and cryoprecipitate supply. Cerus and BCA plan collaborative training and distribution to expand access and adoption of pathogen reduction technology.
Cerus (Nasdaq: CERS) reported record third-quarter 2025 results with total revenue $60.2M (+19% YoY) and product revenue $52.7M (+15% YoY). Government contract revenue was $7.5M (+63% YoY). Q3 product gross margin was 53.4% versus 56.9% a year ago. Hospital demand for INTERCEPT fibrinogen complex (IFC) volumes rose ~110% YoY; Q3 U.S. IFC sales were $3.9M.
Q3 GAAP net loss narrowed to $0.02M (near breakeven); non-GAAP adjusted EBITDA was $5.0M. Cash and short-term investments were $78.5M at Sept 30, 2025. Full-year 2025 product revenue guidance raised to $202M–$204M (12%–13% growth); IFC guidance set at $16M–$17M.
Cerus (Nasdaq: CERS) will host an industry workshop on INTERCEPT Fibrinogen Complex (IFC) at the 2025 AABB Annual Meeting in San Diego, Oct 25–28, 2025.
The workshop is scheduled for Oct 27, 2025 at 7:00 a.m. PT and features blood center and blood bank speakers; a replay will be posted on Cerus’ product site about one week after the event. Cerus will also present 18 related abstracts and exhibit at booth #1713.
Cerus Corporation (Nasdaq: CERS) will release its third quarter 2025 financial results on November 6, 2025 after market close.
The company will host a conference call and webcast on the same day at 4:30 P.M. ET to discuss results, business overview, and outlook. Investors can access the live webcast and presentation slides on Cerus’ Investor Relations website and may register to join the call; attendees are encouraged to log in 10 minutes early. A replay will be posted approximately three hours after the call and remain available through November 27, 2025.